Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047915 | 1.00 | MEN1 (0.41) | MEN1KMT2AHPGDGPR119RECQL | |
| SCHEMBL6003485 | 0.76 | HPGD (0.46) | MEN1KMT2AHPGDGPR119RECQL | |
| SCHEMBL23267860 | 0.76 | HPGD (0.48) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL5570935 | 0.75 | EPHX1 (0.47) | MEN1KMT2AHPGDGPR119RECQL | |
| SCHEMBL2082838 | 0.75 | — | — | |
| SCHEMBL2082840 | 0.75 | — | — | |
| SCHEMBL34461286 | 0.75 | RECQL (0.48) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL23783193 | 0.72 | HPGD (0.43) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL4711418 | 0.72 | HPGD (0.55) | MEN1KMT2AHPGDGPR119RECQL | |
| SCHEMBL26098762 | 0.72 | GPR119 (0.53) | HPGDGPR119RECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768987-B1 | (R/S) RIFAMYCIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | CUMBRE PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1768987-B1 | (R/S) RIFAMYCIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | CUMBRE PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7226931-B2 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226931-B2 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226931-B2 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1768987-A1 | (R/S) RIFAMYCIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Cumbre Pharmaceuticals Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006012443-A1 | (R/S) RIFAMYCIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | CUMBRE PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019986-A1 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019986-A1 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions | RPS6KA1, RIF1, RPS27L | MEN1 1811/4885KMT2A 2967/4885HPGD 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.